Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1177-1186

  O'Doherty, Catherine ^b   Favorov, Alexander ^c,d   Heggarty, Shirley ^e   Graham, Colin ^e   Favorova, Olga ^f   Ochs, Michael ^d   Hawkins, Stanley ^g   Hutchinson, Michael ^h   O'Rourke, Killian ^h   Vandenbroeck, Koen ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^g ROYAL VICTORIA HOSPITAL   (United Kingdom)

^h ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

APSampler; Bayesian statistics; IFN ; Multiple sclerosis; Pharmacogenomics; Polymorphism

Indexed keywords

ADENINE; ALPHA4 INTEGRIN; BETA INTERFERON; BINDING PROTEIN; CASPASE 10; CASPASE 2; CASPASE 3; CASPASE 7; CYTOSINE; DOPAMINE 3 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; GUANINE; GUANINE NUCLEOTIDE BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 1BETA; JANUS KINASE 1; JANUS KINASE 2; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE; PROTEIN INHIBITOR OF ACTIVATED STAT1; PROTEIN KINASE R; STAT1 PROTEIN; THYMINE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACCURACY; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DATA MINING; DRUG RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOMODULATION; IRELAND; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL DECISION MAKING; MONTE CARLO METHOD; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT CARE; POLYMERASE CHAIN REACTION; PREDICTION; PROBABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME;

EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HUMANS; INTERFERON-BETA; IRELAND; MALE; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC;

EID: 70449504564     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.41     Document Type: Article

References (56)

1. Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group: Randomised double-blind placebo-controlled study of interferon β-1α in relapsing/ remitting multiple sclerosis. Lancet 352(9139), 1498-1504 (1998).
2. Martinez-Forero I, Pelaez A, Villoslada P: Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin. Pharmacother. 9(17), 3053-3067 (2008). > Discussion of current state and challenges ahead in pharmacogenomics research in multiple sclerosis (MS).
3. Rudick RA, Goodkin DE, Jacobs LD et al.: Impact of interferon β-1α on neurologic disability in relapsing multiple sclerosis. Neurology 49(2), 358-363 (1997).
4. The IFNB Multiple Sclerosis Study Group: Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655-661 (1993).
5. Villoslada P, Barcellos LF, Rio J et al.: The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β. J. Neuroimmunol. 130(1-2), 194-201 (2002). (Pubitemid 35240007)
6. Fernandez O, Fernandez V, Mayorga C et al.: HLA class II and response to interferon-β in multiple sclerosis. Acta Neurol. Scand. 112(6), 391-394 (2005). (Pubitemid 41695719)
7. Sriram U, Barcellos LF, Villoslada P et al.: Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun. 4(2), 147-152 (2003).
8. Leyva L, Fernandez O, Fedetz M et al.: IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-β treatment response. J. Neuroimmunol. 163(1-2), 165-171 (2005). (Pubitemid 40692959)
9. Cunningham S, Graham C, Hutchinson M et al.: Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin. Pharmacol. Ther. 78(6), 635-646 (2005). ■■ First large-scale study of the pharmacogenomics of IFN-β in MS based on identification of polymorphisms in 100 type I IFN-inducible genes.
10. Weinstock-Guttman B, Tamano-Blanco M, Bhasi K, Zivadinov R, Ramanathan M: Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients. J. Neuroimmunol. 182(1-2), 236-239 (2007). (Pubitemid 46026717)
11. Byun E, Caillier SJ, Montalban X et al.: Genome-wide pharmacogenomic ana lysis of the response to interferon b therapy in multiple sclerosis. Arch. Neurol. 65(3), 337-344 (2008). ■■ First genome-wide screen for identification of genetic markers for response to IFN-β in MS based on genotyping of DNA pools for 100K SNPs.
12. Vandenbroeck K, Matute C: Pharmacogenomics of the response to IFN-β in multiple sclerosis: ramifications from the first genome-wide screen. Pharmacogenomics 9(5), 639-645 (2008). ■ Discussion of current status of MS pharmacogenomics research based on polymorphic markers. (Pubitemid 351803921)
13. O'Doherty C, Villoslada P, Vandenbroeck K: Pharmacogenomics of type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev. 18(3-4), 211-222 (2007).
14. Baranzini SE, Mousavi P, Rio J et al.: Transcription-based prediction of response to IFNβ using supervised computational methods. PLoS Biology 3(1), E2 (2005). ■■ Pioneering study identifying transcriptional markers of response to IFN-β. Design and use of advanced data-mining and predictive modelling approaches.
15. Poser CM, Paty DW, Scheinberg L et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13(3), 227-231 (1983). (Pubitemid 13158528)
16. Favorov AV, Andreewski TV, Sudomoina MA, Favorova OO, Parmigiani G, Ochs MF: A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics 171(4), 2113-2121 (2005). ■■ Description of the APSampler algorithm for exploration of allelic combinations associated with outcome. APSampler was applied in the present study.
17. Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS: Interferon a regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37(3), 610-621 (2003). (Pubitemid 36258783)
18. Weinstock-Guttman B, Badgett D, Patrick K et al.: Genomic effects of IFN-β in multiple sclerosis patients. J. Immunol. 171(5), 2694-2702 (2003).
19. Sturzebecher S, Wandinger KP, Rosenwald A et al.: Expression profiling identifies responder and nonresponder phenotypes to interferon-β in multiple sclerosis. Brain 126(Pt 6), 1419-1429 (2003). (Pubitemid 36644386)
20. Bailey DP, Kashyap M, Bouton LA, Murray PJ, Ryan JJ: Interleukin-10 induces apoptosis in developing mast cells and macrophages. J. Leukoc. Biol. 80(3), 581-589 (2006).
21. Bachis A, Colangelo AM, Vicini S et al.: Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J. Neurosci. 21(9), 3104-3112 (2001). (Pubitemid 32323492)
22. Zhong J, Deaciuc IV, Burikhanov R, de Villiers WJ: Lipopolysaccharide- induced liver apoptosis is increased in interleukin-10 knockout mice. Biochim. Biophys. Acta 1762(4), 468-477 (2006).
23. Sarkar D, Leszczyniecka M, Kang DC et al.: Down-regulation of Myc as a potential target for growth arrest induced by human polynucleotide phosphorylase (hPNPaseold-35) in human melanoma cells. J. Biol. Chem. 278(27), 24542-24551 (2003).
24. Novick D, Cohen B, Rubinstein M: The human interferon α/β receptor: characterization and molecular cloning. Cell 77(3), 391-400 (1994). (Pubitemid 24145200)
25. Soilu-Hanninen M, Laaksonen M, Hanninen A, Eralinna JP, Panelius M: Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon β-1α in MS. J. Neuroimmunol. 167(1-2), 175-182 (2005). (Pubitemid 41242299)
26. Graber J, Zhan M, Ford D et al.: Interferon-β-1α induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J. Neuroimmunol. 161(1-2), 169-176 (2005). (Pubitemid 40340885)
27. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon α. Hepatology 30(2), 526-530 (1999).
28. Wergeland S, Beiske A, Nyland H et al.: IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur. J. Neurol. 12(3), 171-175 (2005). (Pubitemid 40278522)
29. Abbas Z, Moatter T, Hussainy A, Jafri W: Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J. Gastroenterol. 11(42), 6656-6661 (2005).
30. Yee LJ, Tang J, Gibson AW, Kimberly R, van Leeuwen DJ, Kaslow RA: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33(3), 708-712 (2001).
31. Bartosik-Psujek H, Stelmasiak Z: The interleukin-10 levels as a potential indicator of positive response to interferon β treatment of multiple sclerosis patients. Clin. Neurol. Neurosurg. 108(7), 644-647 (2006). (Pubitemid 44415291)
32. Muraro PA, Liberati L, Bonanni L et al.: Decreased integrin gene expression in patients with MS responding to interferon-β treatment. J. Neuroimmunol. 150(1-2), 123-131 (2004). (Pubitemid 38481655)
33. Kawanokuchi J, Mizuno T, Kato H, Mitsuma N, Suzumura A: Effects of interferon-β microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology 46(5), 734-742 (2004). (Pubitemid 38292978)
34. Asahina Y, Izumi N, Uchihara M et al.: Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J. Hepatol. 39(3), 421-427 (2003). (Pubitemid 37070260)
35. Knapp S, Yee LJ, Frodsham AJ et al.: Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4(6), 411-419 (2003).
36. Leszczyniecka M, Su ZZ, Kang DC, Sarkar D, Fisher PB: Expression regulation and genomic organization of human polynucleotide phosphorylase, hPNPase(old-35), a type I interferon inducible early response gene. Gene 316, 143-156 (2003).
37. Cosentino M, Zaffaroni M, Marino F et al.: Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J. Neuroimmunol. 133(1-2), 233-240 (2002). (Pubitemid 35346746)
38. Cosentino M, Zaffaroni M, Ferrari M et al.: Interferon-γ and interferon-β affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. J. Neuroimmunol. 162(1-2), 112-121 (2005). (Pubitemid 40503105)
39. Giorelli M, Livrea P, Trojano M: Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-β. J. Interferon Cytokine Res. 25(7), 395-406 (2005).
40. Chen L, Borozan I, Feld J et al.: Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128(5), 1437-1444 (2005).
41. Batocchi AP, Rotondi M, Caggiula M et al.: Leptin as a marker of multiple sclerosis activity in patients treated with interferon-β. J. Neuroimmunol. 139(1-2), 150-154 (2003). (Pubitemid 36700419)
42. Jansen M, Reinhard JF Jr: Interferon response heterogeneity: activation of a pro-inflammatory response by interferon α and β. A possible basis for diverse responses to interferon β in MS. J. Leukoc. Biol. 65(4), 439-443 (1999). (Pubitemid 29160170)
43. Zabetian CP, Anderson GM, Buxbaum SG et al.: A quantitative-trait analysis of human plasma-dopamine β-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 68(2), 515-522 (2001).
44. Schreiner B, Mitsdoerffer M, Kieseier BC et al.: Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 155(1-2), 172-182 (2004). (Pubitemid 39165790)
45. Johnson J, Albarani V, Nguyen M, Goldman M, Willems F, Aksoy E: Protein kinase C α is involved in interferon regulatory factor 3 activation and type I interferon-β synthesis. J. Biol. Chem. 282(20), 15022-15032 (2007). (Pubitemid 47093374)
46. Fimia GM, Evangelisti C, Alonzi T et al.: Conventional protein kinase C inhibition prevents a interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation. J. Virol. 78(23), 12809-12816 (2004). (Pubitemid 39507789)
47. Reich NC, Pfeffer LM: Evidence for involvement of protein kinase C in the cellular response to interferon α. Proc. Natl Acad. Sci. 87(22), 8761-8765(1990).
48. Taniguchi T, Takaoka A: A weak signal for strong responses: interferon-α/β revisited. Nat. Rev. Mol. Cell Biol. 2(5), 378-386 (2001). (Pubitemid 33674050)
49. Liu B, Mink S, Wong KA et al.: PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 5(9), 891-898 (2004). (Pubitemid 39276233)
50. Natsume A, Ishii D, Wakabayashi T et al.: IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 65(17), 7573-7579 (2005).
51. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F: Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-β treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult. Scler. 14(5), 622-630 (2008).
52. Paunovic V, Carroll HP, Vandenbroeck K, Gadina M: Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. Rheumatology 47(6), 771-776 (2008). (Pubitemid 351796359)
53. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H: The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol. 76(2), 314-321 (2004). (Pubitemid 39006944)
54. Haploview www.broad.mit.edu/mpg/haploview
55. APSampler http://astor.com.jhmi.edu/~sasha/ APSampler/
56. SNPper http://snpper.chip.org